Trevi announces interim analysis for Phase 2 CANAL trial in Q1 2022, ends PRISM enrollment Jan 31

Trevi Therapeutics, Inc.

Phase 2 CANAL trial of Haduvio for chronic cough in IPF: interim statistical update planned Q1 2022 based on conditional power.
Top-line data from CANAL expected H1 2022; interim may allow proof-of-concept before full enrollment.
Phase 2b/3 PRISM trial for prurigo nodularis: enrollment ends Jan 31, 2022; top-line data H1 2022.
Top-line data from both trials expected in first half of 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.